Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINC1 | P01008 | 2/20 | 0.55 |
| ▸ | FGF1 | P05230 | 4/20 | 0.52 |
| ▸ | FGF2 | P09038 | 1/20 | 0.52 |
| ▸ | HPSE | Q9Y251 | 9/20 | 0.51 |
| ▸ | F10 | P00742 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18826197 | 0.90 | FGF1 (0.54) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL16316488 | 0.89 | FGF1 (0.64) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL14478760 | 0.87 | SERPINC1 (0.47) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL18539806 | 0.83 | FGF1 (0.50) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL12694971 | 0.83 | FGF1 (0.52) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL12920566 | 0.83 | SERPINC1 (0.51) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL2960806 | 0.83 | FGF1 (0.59) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL2961028 | 0.83 | FGF1 (0.59) | SERPINC1FGF1FGF2HPSEF10 | |
| SCHEMBL4904646 | 0.80 | FGF1 (0.70) | SERPINC1FGF1FGF2HPSE | |
| SCHEMBL14020073 | 0.80 | FGF1 (0.70) | SERPINC1FGF1FGF2HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255992-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | THE AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255992-A1 | COMPOUNDS FOR TREATING AND PREVENTING EXTRACELLULAR HISTONE MEDIATED PATHOLOGIES | HMGB1, HDAC2, H1-3 | SERPINC1 569/4885FGF1 1092/4885FGF2 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.